2016
DOI: 10.3233/jad-160745
|View full text |Cite
|
Sign up to set email alerts
|

Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease

Abstract: Background: Souvenaid® (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium), was developed to support the formation and function of neuronal membranes.Objective: To determine effect sizes observed in clinical trials of Souvenaid and to calculate the number needed to treat to show benefit or harm.Methods: Data from all three reported randomized controlled trials of Souvenaid in Alzheimer’s disease (AD) dementia (Souven… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
30
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
3

Relationship

2
7

Authors

Journals

citations
Cited by 36 publications
(32 citation statements)
references
References 25 publications
2
30
0
Order By: Relevance
“…In a post hoc analysis, B-vitamin supplementation in patients with MCI resulted in reduced brain atrophy and increased cognitive improvement, which was limited to the subgroup of patients that had the highest blood-level of n3-FAs, especially DHA (264,283,284). A set of four clinical trials that were based on the FC multi-nutrient formulation showed improved memory performance (285,286), increased neurophysiological measures of synaptic activity, and enhanced functional connectivity in the brain (286,287), but did not slow cognitive decline in mild to moderate AD (288,289). Results from the fourth clinical trial, which studies this intervention in prodromal (pre dementia) AD, have not yet been published.…”
Section: Multi-nutrientsmentioning
confidence: 99%
“…In a post hoc analysis, B-vitamin supplementation in patients with MCI resulted in reduced brain atrophy and increased cognitive improvement, which was limited to the subgroup of patients that had the highest blood-level of n3-FAs, especially DHA (264,283,284). A set of four clinical trials that were based on the FC multi-nutrient formulation showed improved memory performance (285,286), increased neurophysiological measures of synaptic activity, and enhanced functional connectivity in the brain (286,287), but did not slow cognitive decline in mild to moderate AD (288,289). Results from the fourth clinical trial, which studies this intervention in prodromal (pre dementia) AD, have not yet been published.…”
Section: Multi-nutrientsmentioning
confidence: 99%
“…The role of the micronutrient choline and other methyl-donors in the functioning of the mature brain has been studied in animal models and in humans. For example, choline has been shown to exert neuroprotective effects by lessening or delaying symptoms of cognitive impairments and memory decline with aging [89][90][91], symptoms often seen in individuals suffering from neurodegenerative disorders such as Alzheimer's disease. Could then an individualized nutrition-based approach be adopted early on in life to boost mental health or delay the progression of these debilitating diseases with aging?…”
Section: Choline Other Methyl Donors and The Aging Brainmentioning
confidence: 99%
“…Here, effect size has emerged as a convenient lingua franca for comparing performance between study cohorts. 8 These are usually comparisons of "typical controls" with those who meet generally accepted criteria for diagnostic categories, such as can be found in the World Health Organization (WHO) International Statistical Classification of Diseases and Related Health Problems. 9 In psychiatry, the Diagnostic and Statistical Manual of Mental Disorders (DSM) is also commonly applied.…”
Section: Assessing Cognition In Patients With Depressionmentioning
confidence: 99%